Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARBLE
2014-001983-36Phase 2Terminated
- Sponsor
- AIO-Studien
- Start
- Mar 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of afatinib, pemetrexed, cisplatin and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AIO-Studien. Primary endpoint: Progression-free survival. Started Mar 2015; status: terminated.
02
Drugs
afatinibpemetrexedcisplatincarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-001983-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001983-36.